Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, summarises data on the management of patients with multiple myeloma that were presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition.
Highlights include IFM/DFCI 2009, a phase 3 trial of autologous transplantation for multiple myeloma; Tourmaline-MM1, a phase 3 trial of ixazomib in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma; an update on Eloquent-2, a phase 3 trial of elotuzumab in combination with lenalidomide/dexamethasone for relapsed/refractory multiple myeloma; GEN505, a trial of daratumumab monotherapy in heavily pretreated relapsed or refractory multiple myeloma; subgroup analysis from Aspire, a phase 3 trial of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed multiple myeloma based on cytogenetic risk status; and subgroup analysis from Endeavor, a phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma based on cytogenetic risk status.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates